Autres langues Synthaverse S.A.

Actions

SVE

PLBMDLB00018

Marché Fermé - Warsaw S.E. Autres places de cotation 17:55:54 10/05/2024			Varia. 5j.	Varia. 1 janv.
4,94 ^PLN	+2,70%		+2,07%	+15,69%

10/04	Synthaverse S.A. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Synthaverse S.A. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04
Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11
Synthaverse S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	20/09/23
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Ticker to SVE from BML	18/07/23
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. will Change its Name to SYNTHAVERSE S.A	18/07/23
BIOMED-LUBLIN WytwÃ³rnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/05/23
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	20/04/23
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	07/11/22
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) dropped from S&P Global BMI Index	19/09/22
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	07/09/22
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/05/22
BIOMED-LUBLIN Wytw?rnia Surowic i Szczepionek S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/11/21
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 13.398489 million in funding	27/09/21
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	31/08/21
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Announces Earnings Results for the First Quarter of 2021	28/05/21
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm	04/05/21
Biomed-Lublin Wytwórnia Surowic I Szczepionek S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	03/03/21
Biomed-Lublin Secures PLN 29.2 Million in EU Financing for Construction of an R&D Center	01/10/20
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.(WSE:BML) added to S&P Global BMI Index	21/09/20
BIOMED LUBLIN Announces Earnings Results for the First Half Year 2020	15/09/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Synthaverse S.A.

Actions

SVE

PLBMDLB00018

Autres langues

Filtres